These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Colovai AI; Vasilescu ER; Foca-Rodi A; Kim-Schulze S; Hussaini N; D'agati VD; Markowitz GS; Wang C; Cohen DJ; Hardy MA; Suciu-Foca N Hum Immunol; 2005 May; 66(5):501-12. PubMed ID: 15935887 [TBL] [Abstract][Full Text] [Related]
27. Donor bone marrow infusion suppresses alloantibody response in RATG-treated recipients: a correlate of long survival. Thomas JM; Carver FM; Cunningham PR; Gross U; Verbanac KM; Rebellato LM; Riley R; Thomas FT Transplant Proc; 1993 Feb; 25(1 Pt 1):342-3. PubMed ID: 8438326 [No Abstract] [Full Text] [Related]
28. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients. Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282 [TBL] [Abstract][Full Text] [Related]
30. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Gurk-Turner C; Airee R; Philosophe B; Kukuruga D; Drachenberg C; Haririan A Transplantation; 2008 May; 85(10):1425-30. PubMed ID: 18497682 [TBL] [Abstract][Full Text] [Related]
31. T cell-specific activity in rabbit anti-human thymocyte globulin. Correlation with immunosuppresive activity in nonhuman primates. Thomas JM; Williams EA; Thomas FT; Millington GM Transplantation; 1978 Mar; 25(3):97-102. PubMed ID: 417439 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes. Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613 [TBL] [Abstract][Full Text] [Related]
33. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal. Tsapepas DS; Mohan S; Tanriover B; Dube G; Crew RJ; Cohen DJ; Hardy MA; Sandoval PR; Ratner LE Transplantation; 2012 Aug; 94(4):325-30. PubMed ID: 22814328 [TBL] [Abstract][Full Text] [Related]
34. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation. Panigrahi A; Deka R; Bhowmik D; Tiwari SC; Mehra NK Transplant Proc; 2004 Jun; 36(5):1336-9. PubMed ID: 15251326 [TBL] [Abstract][Full Text] [Related]
35. Modern approaches to combining sirolimus with calcineurin inhibitors. Stevens RB Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901 [TBL] [Abstract][Full Text] [Related]
36. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503 [TBL] [Abstract][Full Text] [Related]
37. Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients. Laftavi MR; Pankewycz O; Feng L; Said M; Patel S Immunol Invest; 2015; 44(4):373-84. PubMed ID: 25942348 [TBL] [Abstract][Full Text] [Related]
38. A prostaglandin-dependent immunoregulatory mechanism activated by in vivo administration of antithymocyte globulin. Thomas JM; Carver FM; Fahrenbruch GB; Hall WR; Deepe RM; Thomas FT Surgery; 1983 Aug; 94(2):384-91. PubMed ID: 6224306 [TBL] [Abstract][Full Text] [Related]